文献速递MDS 与骨髓增殖性肿瘤

端粒酶抑制剂伊美司他能够清除骨髓纤维化干细胞和祖细胞

Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells.
PubMed 文献 · Blood Adv · 2018-01-01

研究用体外造血祖细胞实验和体内造血干细胞实验,观察伊美司他对原代正常与骨髓纤维化(MF)干/祖细胞的作用。伊美司他减少MF而非脐血或正常CD34+ALDH+细胞及集落形成,清除JAK2V617F+患者的突变祖细胞;在移植MF脾CD34+细胞的小鼠中,15 mg/kg每周3次共4周显著降低人MF细胞嵌合及突变供体细胞比例,停药后维持至少3个月,伴端粒酶活性抑制和凋亡诱导。作者认为伊美司他在MF患者中的疗效可能源于MF干/祖细胞对其更敏感及给药方案强度。

要点

  • 伊美司他减少MF来源的集落形成祖细胞及CD34+ALDH+细胞,对正常或脐血来源无此作用。
  • 伊美司他可清除JAK2V617F+ MF患者的突变造血祖细胞。
  • 小鼠中15 mg/kg每周3次共4周显著降低人MF细胞嵌合,停药后维持至少3个月。

核心结论

  • 作者认为伊美司他在MF患者中的疗效可能归因于MF干/祖细胞较正常干/祖细胞对伊美司他更敏感,以及伊美司他给药方案的强度。

研究设计与样本

  • 研究采用体外造血祖细胞实验和体内造血干细胞实验,检测伊美司他对原代正常与骨髓纤维化(MF)造血干细胞/祖细胞的作用。
  • 体内实验使用预先移植了MF脾CD34+细胞的免疫缺陷小鼠,伊美司他剂量为15 mg/kg,每周3次,共4周。

主要发现

  • 伊美司他处理CD34+细胞后,MF来源的集落形成单位-粒细胞/巨噬细胞、爆式红系集落形成单位和集落形成单位-粒细胞/红系/巨噬细胞/巨核细胞数量减少,而脐血来源未见减少。
  • 伊美司他减少MF来源而非正常来源的CD34+ALDH+细胞,且不受患者突变状态影响。
  • 伊美司他处理导致JAK2V617F+ MF患者的突变造血祖细胞被清除。
  • 在移植MF脾CD34+细胞的免疫缺陷小鼠中,伊美司他对正常严重联合免疫缺陷 repopulating 细胞达到的嵌合程度影响有限,但显著降低人MF细胞嵌合程度及突变供体细胞比例。
  • 上述效应在停药后至少维持3个月,并与端粒酶活性抑制和凋亡诱导相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical trials of imetelstat therapy have indicated that this telomerase inhibitor might have disease-modifying effects in a subset of patients with myelofibrosis (MF). The mechanism by which imetelstat induces such clinical responses has not been clearly elucidated. Using in vitro hematopoietic progenitor cell (HPC) assays and in vivo hematopoietic stem cell (HSC) assays, we examined the effects of imetelstat on primary normal and MF HSCs/HPCs. Treatment of CD34+ cells with imetelstat reduced the numbers of MF but not cord blood HPCs (colony-forming unit-granulocyte/macrophage, burst-forming unit-erythroid, and colony-forming unit-granulocyte/erythroid/macrophage/megakaryocyte) as well as MF but not normal CD34+ALDH+ cells irrespective of the patient's mutational status. Moreover, imetelstat treatment resulted in depletion of mutated HPCs from JAK2V617F+ MF patients. Furthermore, treatment of immunodeficient mice that had been previously transplanted with MF splenic CD34+ cells with imetelstat at a dose of 15 mg/kg, 3 times per week for 4 weeks had a limited effect on the degree of chimerism achieved by normal severe combined immunodeficiency repopulating cells but resulted in a significant reduction in the degree of human MF cell chimerism as well as the proportion of mutated donor cells. These effects were sustained for at least 3 months after drug treatment was discontinued. These actions of imetelstat on MF HSCs/HPCs were associated with inhibition of telomerase activity and the induction of apoptosis. Our findings indicate that the effects of imetelstat therapy observed in MF patients are likely attributable to the greater sensitivity of imetelstat against MF as compared with normal HSCs/HPCs as well as the intensity of the imetelstat dose schedule.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Wang X, Hu CS, Petersen B, et al. Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells. Blood Adv. 2018. PMID: 30242099. doi:10.1182/bloodadvances.2018022012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。